California doctor on virus cases surge: ‘We’re worried the system will be overwhelmed with patients’ - Yahoo Finance

QuantumScape, a battery developer for electric vehicle use, began trading on the New York Stock Exchange today following a SPAC merger.

And that has them seeking stocks that are primed for gains.

Against this backdrop, Goldman Sachs analysts are pounding the table on three stocks in particular, noting that each could surge over 40% in the year ahead.

To get those investors, the company went public this past October, selling 5.5 million shares at an opening price of $14.10 per share.Among the healthcare name's fans is Goldman Sachs analyst Graig Suvannavejh.

Among a field of multiple competitors, CDAK has made the most significant progress on both fronts, and as such we view their technology platform as best-in-class.”"Given share underperformance (-37%) since the IPO, we find risk/reward highly compelling at current levels, and with key 2021 data sets to provide potential de-risking and positive share inflection," the analyst concluded.Suvannavejh rates CDAK a Buy, and his $29 price target shows the extent of his confidence – it implies a 222% upside for the coming year.

The stock is selling for $8.90, and its $24 average price target implies a 166% one-year upside potential.

(See CDAK stock analysis on TipRanks)Arcutis Biotherapeutics (ARQT)Acrutis is a pioneering researcher in the treatment of dermatological disease.

Feedback from regulators was broadly encouraging, in particular, acknowledging the robust long-term safety data being generated by ARQT for ARQ-151 in plaque psoriasis…”Accordingly, Suvannavejh rates ARQT a Buy, and sets a $36 price target that indicates room for 40% upside growth in 2021.

The stock’s average price target is $37, suggesting a 44% upside from current levels.

(See ARQT stock analysis on TipRanks)Oak Street Health (OSH)With the last stock, we move from medical research to medical care.

A planned expansion in Texas, involving a partnership with Walmart, is also proceeding as planned, and Oak Street has opened its first Walmart Community Clinic the Dallas-Fort Worth area city of Carrollton.Robert Jones, covering this stock for Goldman, set a $74 price target to back his Buy rating.

The stock is selling for $46.94, and its $61.29 average price target suggests it has a ~31% upside for the coming year.

(See OSH stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts.

You'd be sitting on $612,162 if you invested $1k in each of these stocks picked by Motley Fool.

John Buckingham of The Prudent Speculator investment newsletter provides a special screen of stocks for MarketWatch premium subscribers.

If I figure in the private mortgage I wrote for my daughter—which I consider comparable to a bond investment—the mix is more like 67% stocks and 33% conservative investments.

After what can only be described as a tumultuous year, with 2021 at the gate, both Wall Street and Main Street are exuding a sense of optimism.Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) have contributed toward the renewed sense of hope; Positive late stage data from the pharma companies’ respective Covid-19 vaccine programs has brought with it the very real prospect the pandemic could soon be over.However, looking beyond the near-term implications, Leerink analyst Mani Foroohar believes that among this select list of companies, one’s outlook is not all that rosy.The investment thesis for Moderna, says Foroohar, just doesn’t hold water.The analyst rates MRNA an Underperform (i.e. Sell) along with a $60 price target.

Should Foroohar’s thesis play out, investors would see a 53% drop from current levels.

Furthermore, amongst mRNA vaccine makers, the analyst expects Moderna to play second fiddle to Pfizer/BioNTech’s offering.Moreover, with shares already up by a mighty 550% year-to-date and looking beyond the Covid-19 vaccine opportunity, the biotech’s remaining options, according to Forhoohar, just don’t cut the mustard.“Elsewhere in the pipeline, we see little near-term news flow to drive share outperformance for a company of MRNA’s market cap,” the analyst said.

Yet, considering the average price target stands at $108.62, the analysts anticipate ~15% downside over the coming months.

(See MRNA stock analysis on TipRanks)To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst.

Ford has been among the worst-performing auto stocks during the past five years.

Check out these S&P; 500 stocks that pay an annual dividend yield of over 7%.

Citron Research editor and notorious short seller added another name to his holiday short list on Friday.In a tweet, Left said he has a short position in Palantir Technologies Inc (NYSE: PLTR) after the stock has more than tripled from its $10 direct listing price back on Sept.

Left is shorting Palantir and with a $20 price target by the end of the year, suggesting more than 50% downside from current levels."What a run the past month for all.

Does not take a ball of crystal to know this will fall back to Arda," Left tweeted.Related Link: Citron Says It's 'Insulting' To Call Blink Charging An EV StockOther Short Bets On EV Stocks: His valuation-based short thesis for Palantir is similar to his short thesis for electric vehicle stock Nio Inc - ADR (NYSE: NIO) back on Nov.

In November 2018, Left compared Nio to Tesla Inc (NASDAQ: TSLA) when Nio was trading at around $7 per share, but he said this month that investors should take profits on the stock after it has gained nearly 2,300% in the past year."After a rocky road of trading, NIO has found itself in unchartered territory that can never be justified by its current standing in the China EV market or its near-term prospects," Left said of Nio.Left has also recently called Electrameccanica Vehicles Corp (NASDAQ: SOLO) "a complete joke" and EV charging station stock Blink Charging Co (NASDAQ: BLNK) a "total scheme."Benzinga's Take: Short sellers that have focused on fundamental valuation analysis have been getting killed for years now, especially when it comes to betting against EV stocks.

The fact that Left specifically mentioned his $20 price target for Palantir is for "2020" suggests it may simply be a short-term bet on a correction rather than a longer-term commentary on the stock.See more from Benzinga * Click here for options trades from Benzinga * Q3 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios(C) 2020 Benzinga.com.

A“double up” strategy lets investors keep their stock, avoiding realizing losses, and position for a rebound at more favorable prices.

The Nio Analyst: Analyst Ming Hsun Lee maintained a Buy rating on Nio with a $54.70 price target.

The Nio Thesis: BofA's positive view on Nio is predicated on its long-term share gain potential in the premium EV market and improving profitability along with "rising scale," Hsun Lee said in a Friday note.Nio is planning to introduce its first sedan model and reveal more details on NP2 at its Nio Day scheduled for January 2021, the analyst said.

The company is modeling vehicle gross margin of about 15%-20% over the long term, Hsun Lee said.The company is open to adopting Lidar in the future, the analyst said.

Related Link: EV Stocks Continue Rally As Short Sellers Question Valuations Nio plans to expand point of sales, including Nio Houses and Nio Spaces, from 187 to 200 by the end of 2020, and add another 100 in 2021, he said.

Related Link: High-Flying Chinese EV Stocks Hit Roadblock Amid Domestic Regulatory Scrutiny A Nio ES6 SUV.

Latest Ratings for NIO DateFirmActionFromTo Nov 2020Deutsche BankMaintainsBuy Nov 2020B of A SecuritiesMaintainsBuy Oct 2020JP MorganUpgradesNeutralOverweight View More Analyst Ratings for NIO View the Latest Analyst RatingsSee more from Benzinga * Click here for options trades from Benzinga * High-Flying Chinese EV Stocks Hit Roadblock Amid Domestic Regulatory Scrutiny * EV Stocks Continue Rally As Short Sellers Question Valuations(C) 2020 Benzinga.com.

The consumer-discretionary sector has gained 29% in 2020, making it the second-best performer this year, behind only tech.

2020 has been a year like no other, with earth shattering events hogging the headlines.

But the year has also provided many interesting sub-plots.

The video conferencing platform has become a household name in the year of Covid-19, but for investors, ZM stock has also been the gift that keeps on giving?

Ahead of next week’s earnings report, RBC analyst Alex Zukin expects Zoom to keep on outperforming.“As we enter the fiscal 3Q report, we continue to see material upside to guidance/consensus expectations both in the quarter and for the year,” the 5-star analyst said.

“With investor debate starting to center on the company’s ability to comp the tremendous growth achieved in FY21, our upside scenario still points to ~60% revenue growth in FY22.”Zukin, who's ranked at 5 out of over 7,100 analysts on TipRanks, rates ZM an Outperform (i.e. Buy) along with a $600 price target?

Overall, analysts expect the stock to stay range-bound for the foreseeable future, as the $477.67 average price target indicates.

(See Zoom stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst.